-0,40 %
+1,84 %
-5,78 %
-76,27 %
-75,07 %
-79,22 %
-82,89 %
-88,24 %
-85,10 %
Faron is a global, clinical-stage biopharmaceutical company, focused on tackling cancers via novel immunotherapies. Its mission is to bring the promise of immunotherapy to a broader population by uncovering novel ways to control and harness the power of the immune system. The Company's lead asset is bexmarilimab, a novel anti-Clever-1 humanized antibody, with the potential to remove immunosuppression of cancers through reprogramming myeloid cell function. Bexmarilimab is being investigated in Phase I/II clinical trials as a potential therapy for patients with hematological cancers in combination with other standard treatments.
Læs mereMarkedsværdi
113,37 mio. EUR
Aktieomsætning
51,4 t EUR
P/E (adj.) (26e)
-4,82
EV/EBIT (adj.) (26e)
-5,56
P/B (26e)
86,33
EV/S (26e)
26.403,74
Udbytteafkast, % (26e)
-
